Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
226950.KQ Stock Summary
Top 10 Correlated ETFs
226950.KQ
In the News
226950.KQ Financial details
Company Rating
Strong Buy
Market Cap
250.2B
Income
-19.1B
Revenue
17.06B
Book val./share
3112.06
Cash/share
1618.29
Dividend
-
Dividend %
-
Employees
73
Optionable
No
Shortable
Yes
Earnings
10 May 2024
P/E
-8.69
Forward P/E
-
PEG
10.17
P/S
36.9
P/B
5.82
P/C
10.29
P/FCF
-7.67
Quick Ratio
0.82
Current Ratio
0.96
Debt / Equity
0.73
LT Debt / Equity
0.7
-
-
EPS (TTM)
-1.3K
EPS next Y
-
EPS next Q
-
EPS this Y
-6.95%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
3.73%
Revenue last 5Y
72.1%
Revenue Q/Q
418.79%
EPS Q/Q
-157.65%
-
-
-
-
SMA20
1.54%
SMA50
2.45%
SMA100
20.78%
Inst Own
-
Inst Trans
-
ROA
-27%
ROE
-53%
ROC
-0.41%
Gross Margin
98%
Oper. Margin
-366%
Profit Margin
-377%
Payout
-
Shs Outstand
16.46M
Shs Float
11.82M
-
-
-
-
Target Price
-
52W Range
12900.0-25950.0
52W High
-35.84%
52W Low
+29.07%
RSI
51
Rel Volume
0.5
Avg Volume
127.89K
Volume
63.91K
Perf Week
9.54%
Perf Month
18.34%
Perf Quarter
7.01%
Perf Half Y
6.73%
-
-
-
-
Beta
0.816
-
-
Volatility
559%, 940.98%
Prev Close
3.03%
Price
16650
Change
-1.01%
226950.KQ Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 86.8 | 188.13 | 268.48 | 680.16 | 1.18K | |
Net income per share | -1.1K | -1.47K | -2.17K | -1.42K | -1.32K | |
Operating cash flow per share | -824.26 | -285.82 | -1.39K | -2.24K | -1.47K | |
Free cash flow per share | -907.03 | -374.14 | -3.31K | -2.42K | -2.1K | |
Cash per share | 2.73K | 5.18K | 3.64K | 4.52K | 1.8K | |
Book value per share | 3.21K | 3.44K | 1.35K | 4.81K | 3.46K | |
Tangible book value per share | 3.1K | 3.26K | 1.26K | 4.68K | 3.49K | |
Share holders equity per share | 3.21K | 3.44K | 1.35K | 4.81K | 3.46K | |
Interest debt per share | 1.63 | 1.1K | 2.9K | 3.15K | 2.77K | |
Market cap | 414.09B | 418.24B | 561.13B | 291.88B | 219.18B | |
Enterprise value | 409.36B | 421.44B | 564.06B | 330.94B | 246.56B | |
P/E ratio | -28.85 | -21.58 | -18.88 | -14.97 | -11.47 | |
Price to sales ratio | 366.34 | 169.04 | 152.71 | 31.32 | 12.84 | |
POCF ratio | -38.58 | -111.26 | -29.45 | -9.51 | -10.35 | |
PFCF ratio | -35.06 | -84.99 | -12.38 | -8.79 | -7.25 | |
P/B Ratio | 9.91 | 9.24 | 30.3 | 4.43 | 4.4 | |
PTB ratio | 9.91 | 9.24 | 30.3 | 4.43 | 4.4 | |
EV to sales | 362.16 | 170.33 | 153.51 | 35.51 | 14.45 | |
Enterprise value over EBITDA | -28.54 | -28 | -24.94 | -16.22 | -15.86 | |
EV to operating cash flow | -38.14 | -112.11 | -29.6 | -10.79 | -11.65 | |
EV to free cash flow | -34.66 | -85.64 | -12.44 | -9.96 | -8.15 | |
Earnings yield | -0.03 | -0.05 | -0.05 | -0.07 | -0.09 | |
Free cash flow yield | -0.03 | -0.01 | -0.08 | -0.11 | -0.14 | |
Debt to equity | 0 | 0.32 | 2.01 | 0.61 | 0.73 | |
Debt to assets | 0 | 0.18 | 0.43 | 0.3 | 0.35 | |
Net debt to EBITDA | 0.33 | -0.21 | -0.13 | -1.91 | -1.76 | |
Current ratio | 13.59 | 15.38 | 1.29 | 1.64 | 4.9 | |
Interest coverage | -2.7K | -67.94 | -9.97 | -7.64 | -5.21 | |
Income quality | 0.75 | 0.19 | 0.65 | 1.09 | 1.11 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.16 | 0.09 | 0.1 | 0.05 | 0 | |
Research and developement to revenue | 7.94 | 3.83 | 3.87 | 1.77 | 1.04 | |
Intangibles to total assets | 0.03 | 0.03 | 0.02 | 0.02 | 0 | |
Capex to operating cash flow | 0.1 | 0.31 | 1.38 | 0.08 | 0.43 | |
Capex to revenue | -0.95 | -0.47 | -7.15 | -0.27 | -0.53 | |
Capex to depreciation | -1.39 | -0.97 | -16.27 | -1.28 | -3.43 | |
Stock based compensation to revenue | 0.95 | 0.21 | 0.51 | 0.15 | 0 | |
Graham number | 8.92K | 10.69K | 8.13K | 12.41K | 10.14K | |
ROIC | -0.36 | -0.26 | -0.42 | -0.2 | -0.21 | |
Return on tangible assets | -0.33 | -0.25 | -0.35 | -0.15 | -0.19 | |
Graham Net | 2.51K | 2.69K | -1.24K | -247.26 | -1.55K | |
Working capital | 34.69B | 64.56B | 11.87B | 25.5B | 25.58B | |
Tangible asset value | 40.4B | 42.82B | 17.27B | 64.1B | 50.34B | |
Net current asset value | 34.04B | 35.82B | -15.03B | -1.4B | -20.35B | |
Invested capital | 0 | 0.32 | 2.01 | 0.61 | 0.73 | |
Average receivables | 271.52M | 529.74M | 535.16M | 849.5M | 3.22B | |
Average payables | 0 | 1 | 1 | 0 | 0 | |
Average inventory | 500.33M | 335M | 339.15M | 515.65M | 562.79M | |
Days sales outstanding | 174.71 | 76.48 | 54.82 | 44.92 | 113 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 125.52 | 80.14 | 16.34 | 121.58 | 64.71 | |
Receivables turnover | 2.09 | 4.77 | 6.66 | 8.13 | 3.23 | |
Payables turnover | 0 | 692.64M | 0 | 0 | 0 | |
Inventory turnover | 2.91 | 4.55 | 22.34 | 3 | 5.64 | |
ROE | -0.34 | -0.43 | -1.6 | -0.3 | -0.38 | |
Capex per share | -82.77 | -88.32 | -1.92K | -184.97 | -628.46 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 50.55 | 135.09 | 165.75 | 142.21 | 655.81 | |
Net income per share | 482.32 | -509.02 | -645.58 | -345.96 | 199.43 | |
Operating cash flow per share | -624.58 | -453.19 | -496.86 | -417.49 | -51.72 | |
Free cash flow per share | -673 | -558.51 | -679.21 | -509.27 | -270.03 | |
Cash per share | 4.52K | 3.16K | 3.08K | 2.2K | 1.62K | |
Book value per share | 4.81K | 3.33K | 3.07K | 2.87K | 3.11K | |
Tangible book value per share | 4.68K | 3.23K | 2.95K | 2.76K | 3.14K | |
Share holders equity per share | 4.81K | 3.33K | 3.07K | 2.87K | 3.11K | |
Interest debt per share | 2.99K | 2.49K | 3.08K | 2.94K | 2.33K | |
Market cap | 291.88B | 373.38B | 233.62B | 228.55B | 243.34B | |
Enterprise value | 330.94B | 409.97B | 272.4B | 265.84B | 270.71B | |
P/E ratio | 11.04 | -10.98 | -6.59 | -11.6 | 19.04 | |
Price to sales ratio | 421.32 | 165.45 | 102.62 | 112.86 | 23.16 | |
POCF ratio | -34.1 | -49.32 | -34.24 | -38.44 | -293.71 | |
PFCF ratio | -31.65 | -40.02 | -25.04 | -31.52 | -56.25 | |
P/B Ratio | 4.43 | 6.71 | 5.54 | 5.6 | 4.88 | |
PTB ratio | 4.43 | 6.71 | 5.54 | 5.6 | 4.88 | |
EV to sales | 477.72 | 181.66 | 119.66 | 131.28 | 25.77 | |
Enterprise value over EBITDA | -134.37 | -57.12 | -39.33 | -60.74 | 92.19 | |
EV to operating cash flow | -38.67 | -54.15 | -39.92 | -44.72 | -326.75 | |
EV to free cash flow | -35.89 | -43.94 | -29.2 | -36.66 | -62.58 | |
Earnings yield | 0.02 | -0.02 | -0.04 | -0.02 | 0.01 | |
Free cash flow yield | -0.03 | -0.02 | -0.04 | -0.03 | -0.02 | |
Debt to equity | 0.61 | 0.73 | 0.98 | 1 | 0.73 | |
Debt to assets | 0.3 | 0.33 | 0.38 | 0.4 | 0.35 | |
Net debt to EBITDA | -15.86 | -5.1 | -5.6 | -8.52 | 9.32 | |
Current ratio | 1.64 | 1.41 | 1.15 | 0.96 | 4.9 | |
Interest coverage | -4.11 | -9.24 | -8.57 | -5.6 | 2.64 | |
Income quality | 4.26 | 0.89 | 0.77 | 1.21 | -0.26 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.17 | 0.04 | 0.05 | 0.06 | 0 | |
Research and developement to revenue | 0.24 | 2.52 | 2.04 | 1.43 | 0.42 | |
Intangibles to total assets | 0.02 | 0.02 | 0.02 | 0.02 | 0 | |
Capex to operating cash flow | 0.08 | 0.23 | 0.37 | 0.22 | 4.22 | |
Capex to revenue | -0.96 | -0.78 | -1.1 | -0.65 | -0.33 | |
Capex to depreciation | -1.19 | -2.75 | -3.74 | -1.96 | -5.25 | |
Stock based compensation to revenue | 0.67 | 0.24 | 0.24 | 0.16 | 0 | |
Graham number | 7.22K | 6.18K | 6.68K | 4.72K | 3.74K | |
ROIC | -0.02 | -0.09 | -0.09 | -0.06 | 0.03 | |
Return on tangible assets | 0.05 | -0.07 | -0.08 | -0.05 | 0.03 | |
Graham Net | -247.26 | -722.43 | -1.57K | -1.93K | -1.4K | |
Working capital | 25.5B | 17.19B | 5.97B | -1.42B | 25.58B | |
Tangible asset value | 64.1B | 53.97B | 40.53B | 39.28B | 50.34B | |
Net current asset value | -1.4B | -9.1B | -19.65B | -25.64B | -20.35B | |
Invested capital | 0.61 | 0.73 | 0.98 | 1 | 0.73 | |
Average receivables | 1.07B | 2.69B | 3.17B | 2.02B | 3.61B | |
Average payables | 0 | 0 | 0.5 | 0.5 | 0 | |
Average inventory | 554.99M | 666.64M | 678.43M | 689.06M | 582.88M | |
Days sales outstanding | 149.03 | 169.07 | 82.93 | 86.21 | 45.26 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 105.97 | 95.19 | 91.57 | 94.05 | 63.27 | |
Receivables turnover | 0.6 | 0.53 | 1.09 | 1.04 | 1.99 | |
Payables turnover | 0 | 0 | 669.07M | 0 | 0 | |
Inventory turnover | 0.85 | 0.95 | 0.98 | 0.96 | 1.42 | |
ROE | 0.1 | -0.15 | -0.21 | -0.12 | 0.06 | |
Capex per share | -48.42 | -105.32 | -182.35 | -91.78 | -218.31 |
226950.KQ Frequently Asked Questions
What is OliX Pharmaceuticals,Inc stock symbol ?
OliX Pharmaceuticals,Inc is a KR stock and trading under the symbol 226950.KQ
What is OliX Pharmaceuticals,Inc stock quote today ?
OliX Pharmaceuticals,Inc stock price is $16650 today.
Is OliX Pharmaceuticals,Inc stock public?
Yes, OliX Pharmaceuticals,Inc is a publicly traded company.